52-Week Performance Chart

Powered by FactSet Research Systems Inc

Capital Raising Events

More
DR Price Date DR Price (USD) US/Non-US/Total DRS US/Non-US/Total DR Capital Raised
Oct 20, 2017 5.00 3,480,000
0
3,480,000
17,400,000
0
17,400,000

No DR Special Notices are available.

No DR Events are available.

Data provided by Thomson Reuters

Institutional Ownership

TOP INSTITUTIONAL HOLDERS POSITION
Armistice Capital LLC 2,723,966
Cresset Asset Management LLC 822,468
Warberg Asset Management LLC 308,340
TOP MUTUAL FUND HOLDERS POSITION
LUX IM - Global Medtech 10,264
RiverNorth Capital & Income Fund 1,103
RiverNorth Opportunities Fund Inc. 508

Data provided by FactSet Research Systems Inc.

DR Details

DR Symbol AKTX
CUSIP 00972G207
DR Venue NASDAQ Stock Market
DR ISIN US00972G2075
Ratio DR:ORD 1:2000
Local Exchange Not Traded
Underlying ISIN GB00B807GC03
Country United Kingdom
Effective Date Dec 07, 2012
Depositary DB (Sponsored)
Industry Pharma. & Biotech.
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Jan.26 0.23 8,034,139 401,707
Dec.25 0.29 54,249,525 2,465,888
Nov.25 0.49 9,025,176 475,009

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE